Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiang-Fan Chen

Showing results (1-10 of 212) with videos related to

Pageof 22
Sort By:
Drug News & Perspectives|January 1, 2004
The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatmentJiang-Fan Chen
International Review of Neurobiology|September 2, 2014
Adenosine receptor control of cognition in normal and diseaseJiang-Fan Chen
Trends in Molecular Medicine|March 4, 2026
Adenosine signaling: the convergent hub in antidepressant actionZhihui Li, Jiang-Fan Chen
Journal of Experimental Stroke & Translational Medicine|November 2, 2013
Strategies for therapeutic hypometabothermiaShimin Liu, Jiang-Fan Chen
Frontiers in Neuroscience|January 4, 2021
Caffeine and Parkinson's Disease: Multiple Benefits and Emerging MechanismsXiangpeng Ren, Jiang-Fan Chen
Handbook of Experimental Pharmacology|September 23, 2010
Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studiesJiang-Fan Chen, Yijuang Chern
Current Pharmaceutical Design|June 10, 2008
Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptorsJiang-Fan Chen, Felicita Pedata
Parkinsonism & Related Disorders|December 22, 2020
Do caffeine and more selective adenosine A<sub>2A</sub> receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?Jiang-Fan Chen, Michael A Schwarzschild
Purinergic Signalling|April 3, 2020
The belated US FDA approval of the adenosine A<sub>2A</sub> receptor antagonist istradefylline for treatment of Parkinson's diseaseJiang-Fan Chen, Rodrigo A Cunha
Current Neuropharmacology|March 2, 2010
Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognitionHai-Ying Shen, Jiang-Fan Chen
Pageof 22

Showing results (1-10 of 212) with videos related to

Sort By:
Pageof 22
Drug News & Perspectives|January 1, 2004
The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatmentJiang-Fan Chen
International Review of Neurobiology|September 2, 2014
Adenosine receptor control of cognition in normal and diseaseJiang-Fan Chen
Trends in Molecular Medicine|March 4, 2026
Adenosine signaling: the convergent hub in antidepressant actionZhihui Li, Jiang-Fan Chen
Journal of Experimental Stroke & Translational Medicine|November 2, 2013
Strategies for therapeutic hypometabothermiaShimin Liu, Jiang-Fan Chen
Frontiers in Neuroscience|January 4, 2021
Caffeine and Parkinson's Disease: Multiple Benefits and Emerging MechanismsXiangpeng Ren, Jiang-Fan Chen
Handbook of Experimental Pharmacology|September 23, 2010
Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studiesJiang-Fan Chen, Yijuang Chern
Current Pharmaceutical Design|June 10, 2008
Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptorsJiang-Fan Chen, Felicita Pedata
Parkinsonism & Related Disorders|December 22, 2020
Do caffeine and more selective adenosine A<sub>2A</sub> receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?Jiang-Fan Chen, Michael A Schwarzschild
Purinergic Signalling|April 3, 2020
The belated US FDA approval of the adenosine A<sub>2A</sub> receptor antagonist istradefylline for treatment of Parkinson's diseaseJiang-Fan Chen, Rodrigo A Cunha
Current Neuropharmacology|March 2, 2010
Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognitionHai-Ying Shen, Jiang-Fan Chen
Pageof 22